Matinas BioPharma
MTNB
61 hedge funds and large institutions have $67.4M invested in Matinas BioPharma in 2019 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 7 closing their positions.
371% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 7
258% more capital inflows, than outflows
Capital inflows: $6.99M | Capital outflows: $1.96M
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
74% more funds holding
Funds holding: 35 → 61 (+26)
2.08% more ownership
Funds ownership: 16.19% → 18.27% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.61M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$750K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$678K |
| 4 |
ExodusPoint Capital Management
New York
|
+$548K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$355K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Granite Point Capital Management
Boston,
Massachusetts
|
-$946K |
| 2 |
Millennium Management
New York
|
-$341K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$337K |
| 4 |
TI
Telemetry Investments
New York
|
-$272K |
| 5 |
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$16K |
MTNB Hedge Fund Activity: Q4 2019 in Review
61 of the 5,095 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2019, worth a combined $67.4M — up 307% from $16.6M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new MTNB positions and 7 closed out — a net gain of 26 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $1.61M. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $946K sold.
- 61 institutional investors held Matinas BioPharma (MTNB) as of Q4 2019, up from 35 in Q3 2019.
- Funds reported $67.4M of Matinas BioPharma stock for Q4 2019, up 307% quarter-over-quarter.
- 33 funds opened new Matinas BioPharma positions in Q4 2019 and 7 closed out, a net change of +26 holders.
- The largest Matinas BioPharma buyer in Q4 2019 was BlackRock, an estimated $1.61M added.
- The largest Matinas BioPharma seller in Q4 2019 was Granite Point Capital Management, an estimated $946K sold.
Based on aggregated 13F filings for Q4 2019.